-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compared with chemotherapy, pembrolizumab prolonged progression-free survival in patients with newly diagnosed metastatic colorectal cancer with high microsatellite instability or positive mismatch repair deficiency
colorectal cancer
The KEYNOTE-177 study is a randomized, open-label Phase 3 clinical trial conducted at 193 medical centers in multiple countries, enrolling patients 18 years of age and older, ECOG performance status 0-1, and previously untreated microsatellites Patients with metastatic colorectal cancer with high instability or positive mismatch repair deficiency
193 2 2
Between February 11, 2016, and February 19, 2018, a total of 852 patients were screened , of whom 307 (36%) were randomized to pembrolizumab (n=153) or chemotherapy (n=154) )
Screening 307
36.
33 95
In conclusion, although pembrolizumab demonstrated durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two groups
Pembrolizumab demonstrated durable antitumor activity and fewer treatment-related adverse events, but there was no significant difference in overall survival between the two groups
Original source:
Original source:Diaz Luis A, Shiu Kai-Keen, Kim Tae-Won et al.
Diaz Luis A, Shiu Kai-Keen, Kim Tae-Won et al.
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
[J] .
Lancet Oncol, 2022, https://doi.
org/10.
1016/S1470-2045(22)00197-8.
Leave a comment here